KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Abbott Laboratories (ABT) Debt to Equity (2016 - 2025)

Abbott Laboratories' Debt to Equity history spans 17 years, with the latest figure at $0.25 for Q4 2025.

  • For Q4 2025, Debt to Equity fell 17.33% year-over-year to $0.25; the TTM value through Dec 2025 reached $0.25, down 17.33%, while the annual FY2025 figure was $0.25, 17.33% down from the prior year.
  • Debt to Equity for Q4 2025 was $0.25 at Abbott Laboratories, down from $0.25 in the prior quarter.
  • Across five years, Debt to Equity topped out at $233.97 in Q2 2023 and bottomed at -$2.04 in Q2 2025.
  • The 5-year median for Debt to Equity is $0.27 (2024), against an average of $34.88.
  • The largest annual shift saw Debt to Equity tumbled 249.31% in 2022 before it surged 12124.14% in 2025.
  • A 5-year view of Debt to Equity shows it stood at $0.74 in 2021, then crashed by 249.31% to -$1.1 in 2022, then soared by 6049.89% to $65.53 in 2023, then crashed by 99.55% to $0.3 in 2024, then dropped by 17.33% to $0.25 in 2025.
  • Per Business Quant, the three most recent readings for ABT's Debt to Equity are $0.25 (Q4 2025), $0.25 (Q3 2025), and -$2.04 (Q2 2025).